Form 4: Inmune Bio CFO Options Repriced to $1.50

Inmune Bio's Interim CFO, Cory Randall Ellspermann, had 245,000 stock options repriced to an exercise price of $1.50 per share following stockholder approval.

Summary

• Inmune Bio, Inc. (INMB) repriced 245,000 outstanding stock options held by Interim CFO Cory Randall Ellspermann.
• The exercise price for these options was reduced to $1.50 per share.
• This repricing was effective as of November 18, 2025, and was approved by the Issuer's stockholders.
• The new exercise price of $1.50 represents the closing price of Inmune Bio's common stock on The Nasdaq Capital Market on the repricing date.
• The repriced options were originally granted under the company's 2017, 2019, and 2021 Stock Incentive Plans.
• All other terms and conditions of the repriced options, including vesting schedules, remain unchanged.

Sentiment

Score: 3

Explanation: The repricing of executive stock options to a significantly lower exercise price, matching the current market price, indicates a substantial decline in the company's stock value. While it re-incentivizes the executive, it reflects past underperformance and can be viewed negatively by shareholders due to potential dilution and the signal of a struggling stock.

Positives

• The repricing makes the options significantly more 'in the money' for the Interim CFO, potentially increasing their motivation and retention.
• The new exercise price of $1.50 is substantially lower than the original exercise prices, which ranged from $3.91 to $21.06, providing immediate value to the option holder.
• Stockholder approval for the repricing indicates alignment between management and shareholders on this compensation adjustment.

Negatives

• Option repricing can be viewed negatively by some investors as it effectively grants new options at a lower price, potentially diluting existing shareholder value if the stock price recovers.
• Repricing often occurs when a company's stock price has significantly declined, which could signal underlying performance issues or market dissatisfaction.
• The repricing of options to the current market price ($1.50) suggests that previously granted options were significantly 'out of the money,' indicating a substantial drop in the company's stock value since those grants.

Future Outlook

NA

Management Comments

• Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options")... which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing").
• Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.
• This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact due to implied stock price decline and potential future dilution if the repriced options are exercised.
• Employees (specifically Interim CFO): Positive impact as options become more valuable and provide renewed incentive.

Next Steps

• The repriced options will become exercisable in accordance with their original vesting schedules, subject to the Interim CFO's continued service.

Key Dates

Recommendation

The necessity to reprice executive stock options to a significantly lower market price (from up to $21.06 down to $1.50) strongly suggests a substantial and sustained decline in the company's stock value. This indicates significant underperformance or negative market sentiment. While the repricing aims to re-incentivize management, it comes at the cost of existing shareholder value through potential dilution and signals a lack of confidence in the previous valuation. Investors should consider selling due to the clear indication of past poor performance and the potential for continued weakness.

Keywords

Inmune Bio, INMB, stock options, option repricing, executive compensation, Form 4, SEC filing, Cory Randall Ellspermann, Interim CFO, Nasdaq